Safety and efficacy of combined pneumococcal and influenza vaccinations in patients with coronary artery disease

Safety and efficacy of combined pneumococcal and influenza vaccinations in patients with coronary artery disease - Safety and efficacy of combined pneumococcal and influenza vaccinations in patients with coronary artery disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012017

Enrollment

Registered

2013-10-11

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with coronary artery disease

Interventions

Pneumococcal vaccination Influenza vaccination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who request influenza vaccination 2) Patients with coronary artery disease (1) Patients with >=50% diameter stenosis diagnosed by coronary angiography (2) History of myocardial infarction (3) History of coronary revascularization

Exclusion criteria

Exclusion criteria: 1) History of pneumococcal infection 2) Patients treated with pneumococcal vaccination previously 3) Patients treated with another vaccination within 3 months 4) Patients with allergy against vaccine component, egg, chicken, and chicken-derived ingredients 5) Patients with fever 6) Patients with acute and severe diseases 7) Patients with liver disorder (AST and/or ALT: 2.5 times or larger than upper normal limits) 8) Patients with renal disorder (creatinine level >= 2.0 mg/dL) 9) History of myocardial infarction within 6 months 10) History of coronary revascularization within 3 months 11) Patients with congestive heart failure (NYHA Class III or IV) 12) Patients with poor control diabetes (HbA1c >= 10%) 13) Patients with poor control hypertension (SBP >= 200mmHg or DBP >= 110mmHg) 14) Patients who judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
Safety and efficacy for cardiovascular biomarkers	—

Secondary

Measure	Time frame
Prevalence of influenza and pneumococcal infection, changes of complete blood cell count, liver function, renal function, glucose tolerance, and lipid profiles	—

Countries

Japan

Contacts

Public ContactKazunori Shimada

Juntendo University School of Medicine Department of Cardiology

shimakaz@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026